Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 2
2010 1
2011 1
2012 4
2013 8
2014 4
2015 9
2016 9
2017 4
2018 13
2019 14
2020 21
2021 13
2022 15
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Retraction Note: Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.
Barshidi A, Karpisheh V, Noukabadi FK, Kiani FK, Mohammadi M, Afsharimanesh N, Ebrahimi F, Kiaie SH, Navashenaq JG, Hojjat-Farsangi M, Zolbanin NM, Mahmoodpoor A, Hassannia H, Nami S, Jalali P, Jafari R, Jadidi-Niaragh F. Barshidi A, et al. Among authors: hojjat farsangi m. Pharm Res. 2024 Feb;41(2):407-408. doi: 10.1007/s11095-023-03647-1. Pharm Res. 2024. PMID: 38148385 No abstract available.
Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide.
Khodakarami A, Kashani MA, Nazer A, Kheshti AM, Rashidi B, Karpisheh V, Masjedi A, Abolhasani S, Izadi S, Bagherifar R, Hejazian SS, Mohammadi H, Movassaghpour A, Feizi AAH, Hojjat-Farsangi M, Jadidi-Niaragh F. Khodakarami A, et al. Among authors: hojjat farsangi m. Cell Commun Signal. 2023 Aug 1;21(1):188. doi: 10.1186/s12964-023-01213-1. Cell Commun Signal. 2023. PMID: 37528446 Free PMC article.
Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b+/Gr-1+ myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor model.
Ramezani-Aliakbari K, Khaki-Bakhtiarvand V, Mahmoudian J, Asgarian-Omran H, Shokri F, Hojjat-Farsangi M, Jeddi-Tehrani M, Shabani M. Ramezani-Aliakbari K, et al. Among authors: hojjat farsangi m. Int Immunopharmacol. 2023 Aug;121:110463. doi: 10.1016/j.intimp.2023.110463. Epub 2023 Jun 14. Int Immunopharmacol. 2023. PMID: 37327513
Corrigendum to "Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy" [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240].
Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, Kiani FK, Asl SH, Atyabi F, Hassannia H, Hojjat-Farsangi M, Namdar A, Ghalamfarsa G, Jadidi-Niaragh F. Masjedi A, et al. Among authors: hojjat farsangi m. Nanomedicine. 2023 Jul;51:102690. doi: 10.1016/j.nano.2023.102690. Epub 2023 May 9. Nanomedicine. 2023. PMID: 37167816 No abstract available.
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.
Ghaderi A, Okhovat MA, Lehto J, De Petris L, Manouchehri Doulabi E, Kokhaei P, Zhong W, Rassidakis GZ, Drakos E, Moshfegh A, Schultz J, Olin T, Österborg A, Mellstedt H, Hojjat-Farsangi M. Ghaderi A, et al. Among authors: hojjat farsangi m. Pharmaceutics. 2023 Apr 5;15(4):1148. doi: 10.3390/pharmaceutics15041148. Pharmaceutics. 2023. PMID: 37111634 Free PMC article.
The prognostic and therapeutic potential of HO-1 in leukemia and MDS.
Sadeghi M, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M, Namdar A, Movasaghpour Akbari AA, Jadidi-Niaragh F. Sadeghi M, et al. Among authors: hojjat farsangi m. Cell Commun Signal. 2023 Mar 13;21(1):57. doi: 10.1186/s12964-023-01074-8. Cell Commun Signal. 2023. PMID: 36915102 Free PMC article. Review.
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.
Sadeghi M, Khodakarami A, Ahmadi A, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M, Movasaghpour Akbari AA, Jadidi-Niaragh F. Sadeghi M, et al. Among authors: hojjat farsangi m. Expert Opin Ther Targets. 2022 Dec;26(12):1057-1071. doi: 10.1080/14728222.2022.2170781. Epub 2023 Jan 24. Expert Opin Ther Targets. 2022. PMID: 36683579 Review.
109 results